Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Feb 23;16(1):109-115.
doi: 10.1159/000529470. eCollection 2023 Jan-Dec.

Androgen Deprivation Therapy for Intracranial Metastasis of a Salivary Duct Carcinoma: Case Report

Manuel Rösch  1 , Christian Bieg  2 , Spasenija Savic  3 , Martin Buess  4
Affiliations
Case Reports

Androgen Deprivation Therapy for Intracranial Metastasis of a Salivary Duct Carcinoma: Case Report

Manuel Rösch et al. Case Rep Oncol. .

Abstract

Salivary duct carcinoma (SDC) is a rare subtype of salivary cancers associated with androgen receptor and human epidermal growth factor receptor 2 (HER2/neu) overexpression. It shows a high propensity to give rise to distant metastases mainly to the lung, the bone, and the liver. Intracranial metastases are rare. We report the case of a 61-year-old male patient with SDC developing intracranial metastases. Unresponsive to radiotherapy and anti-HER/neu targeted therapy the intracranial metastases showed a very good partial remission to androgen deprivation therapy with goserelin acetate. This case demonstrates the potential of a highly targeted therapy with a relatively cheap and well-known drug in a patient with a rare disease without other good therapeutic options, which is a good example of modern, personalized medicine.

Keywords: Androgen deprivation; Case report; Intracranial metastasis; Salivary duct carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare to have no conflict of interest related to this work.

Figures

Fig. 1.
Fig. 1.
a Bronchial biopsy with metastasis of the salivary duct carcinoma: HE. b Nuclear androgen receptor immunoexpression (original magnification, ×100).
Fig. 2.
Fig. 2.
Thorax CT-scan axial/transversal before (09/2020, a) and after treatment (04/2021, b).
Fig. 3.
Fig. 3.
MRI of the neurocranium T1-spin echo-sequence with contrast medium. Extra-axial mass at the left cerebellar pontine angle before (08/2020, a) and after treatment (11/2021, b).
Fig. 4.
Fig. 4.
Timeline of the main therapies and responses. P, progressive disease; PR, partial remission; SD, stable disease; Cis/Pem, chemotherapy with cisplatin and pemetrexed; ADT, androgen deprivation therapy.
See this image and copyright information in PMC

References

    1. Kleinsasser O, Klein HJ, Hübner G. [Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1968;192(1):100–5. - PubMed
    1. Simpson RHW. Salivary duct carcinoma: new developments--morphological variants including pure in situ high grade lesions; proposed molecular classification. Head Neck Pathol. 2013;7(Suppl 1):S48–58. 10.1007/s12105-013-0456-x.< - DOI - PMC - PubMed
    1. D’heygere E, Meulemans J, Vander Poorten V. Salivary duct carcinoma. Curr Opin Otolaryngol Head Neck Surg. 2018;26(2):142–51. 10.1097/MOO.0000000000000436. - DOI - PubMed
    1. Venteicher AS, Walcott BP, Sheth SA, Snuderl M, Patel AP, Curry WT, et al. Clinical features of brain metastasis from salivary gland tumors. J Clin Neurosci. 2013;20(11):1533–7. 10.1016/j.jocn.2012.11.024. - DOI - PMC - PubMed
    1. Williams L, Thompson LDR, Seethala RR, Weinreb I, Assaad AM, Tuluc M, et al. Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression. Am J Surg Pathol. 2015;39(5):705–13. 10.1097/PAS.0000000000000413. - DOI - PubMed

Publication types